Reviewing Cybin (OTCMKTS:CYBN) and 9 Meters Biopharma (NASDAQ:NMTR)

9 Meters Biopharma (NASDAQ:NMTR) and Cybin (OTCMKTS:CYBN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Valuation and Earnings

This table compares 9 Meters Biopharma and Cybin”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
9 Meters Biopharma	N/A	N/A	-$43.77 million	($3.46)	N/A
Cybin	$680,000.00	303.41	-$35.93 million	($6.66)	-1.55

Cybin has higher revenue and earnings than 9 Meters Biopharma. Cybin is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Cybin has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.

Institutional & Insider Ownership

22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for 9 Meters Biopharma and Cybin, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
9 Meters Biopharma	0	0	0	0	0.00
Cybin	0	0	1	0	3.00

Given 9 Meters Biopharma’s higher probable upside, research analysts clearly believe 9 Meters Biopharma is more favorable than Cybin.

Profitability

This table compares 9 Meters Biopharma and Cybin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
9 Meters Biopharma	N/A	-584.97%	-159.45%
Cybin	N/A	-93.17%	-84.68%

Summary

Cybin beats 9 Meters Biopharma on 7 of the 12 factors compared between the two stocks.

About 9 Meters Biopharma

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.